Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19376432 | ALBUMIN BINDING PROTEINS AND METHODS OF USE | October 2025 | February 2026 | Allow | 4 | 0 | 0 | Yes | No |
| 19352098 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | October 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19316633 | IL13 AND IL31 BISPECIFIC POLYPEPTIDES AND USES THEREOF | September 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 19304112 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | August 2025 | March 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19302936 | ALLERGY TREATMENT | August 2025 | March 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19297899 | BISPECIFIC AGONISTIC ANTIBODIES TO ACTIVIN A RECEPTOR LIKE TYPE 1 (ALK1) | August 2025 | February 2026 | Allow | 7 | 0 | 0 | Yes | No |
| 19293506 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | August 2025 | January 2026 | Allow | 5 | 0 | 0 | Yes | No |
| 19284312 | ANTIGEN-BINDING PROTEINS AND RELATED METHODS OF USE | July 2025 | February 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19281468 | METHODS FOR TREATING DIABETIC KIDNEY DISEASE AND GLOMERULAR DISEASE | July 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 19276860 | COMPOSITIONS AND METHODS RELATED TO GPRC5D BINDING AGENTS AND VARIANTS THEREOF | July 2025 | October 2025 | Allow | 3 | 0 | 0 | No | No |
| 19275203 | 5T4 BINDING POLYPEPTIDES AND USES THEREOF | July 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 19263325 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | July 2025 | February 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19259911 | KLRB1 BINDING AGENTS AND METHODS OF USE THEREOF | July 2025 | February 2026 | Allow | 8 | 1 | 0 | Yes | No |
| 19259995 | KLRB1 BINDING AGENTS AND METHODS OF USE THEREOF | July 2025 | March 2026 | Allow | 8 | 1 | 0 | Yes | No |
| 19256452 | FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE | July 2025 | January 2026 | Allow | 6 | 2 | 0 | Yes | No |
| 17614288 | COMPOSITION AND METHODS TO TREAT ECTODERMAL DYSPLASIA 2, CLOUSTON TYPE | June 2025 | March 2026 | Allow | 52 | 1 | 1 | Yes | No |
| 19245760 | ALPHA4BETA7 INTEGRIN BINDING PROTEINS AND METHODS OF USE | June 2025 | December 2025 | Allow | 6 | 1 | 1 | No | No |
| 19243022 | IL-18/IL-23 MULTISPECIFIC ANTIGEN BINDING PROTEINS | June 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 19242307 | CAPTURE ANTIBODY AND DETECTION ANTIBODY BINDING MMP9 PROTEIN | June 2025 | August 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19242725 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | June 2025 | February 2026 | Allow | 8 | 1 | 0 | Yes | No |
| 19234136 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | June 2025 | February 2026 | Allow | 8 | 2 | 0 | Yes | No |
| 19231212 | MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO TREAT DUCHENNE MUSCULAR DYSTROPHY | June 2025 | September 2025 | Allow | 4 | 1 | 0 | No | No |
| 19230064 | METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY | June 2025 | November 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19229907 | BISPECIFIC ANTIBODY AND USE THEREOF | June 2025 | January 2026 | Allow | 7 | 2 | 0 | No | No |
| 19228960 | TREATMENT METHOD | June 2025 | January 2026 | Abandon | 8 | 0 | 0 | No | No |
| 19229468 | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF | June 2025 | November 2025 | Allow | 6 | 1 | 0 | No | No |
| 19227795 | PHARMACEUTICAL COMBINATIONS | June 2025 | February 2026 | Allow | 9 | 1 | 0 | Yes | No |
| 19227585 | PHARMACEUTICAL COMPOSITION COMPRISING SUTTERELLA WADSWORTHENSIS AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF COLON CANCER | June 2025 | January 2026 | Allow | 7 | 1 | 0 | No | No |
| 19222996 | METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY | May 2025 | November 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19222494 | ENZYME-DECORATED NANOCATALYSTS | May 2025 | February 2026 | Allow | 9 | 1 | 1 | No | No |
| 19221422 | REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB | May 2025 | March 2026 | Allow | 9 | 1 | 1 | Yes | No |
| 19221315 | MITIGATION OF CRYPTOSPORIDIOSIS USING HYDROGEN PEROXIDE-GENERATING COMPOSITIONS | May 2025 | December 2025 | Allow | 7 | 1 | 0 | No | No |
| 19218154 | ANTI-HUMAN C5 ANTIBODIES | May 2025 | October 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 19217172 | Method of Use for Benzofuran Compounds | May 2025 | February 2026 | Allow | 8 | 1 | 1 | No | No |
| 19217020 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE | May 2025 | August 2025 | Allow | 2 | 0 | 1 | Yes | No |
| 19213402 | ANTIGEN BINDING PROTEINS | May 2025 | December 2025 | Allow | 7 | 1 | 0 | No | No |
| 19211910 | ANTIBODIES AND ANTIBODY FRAGMENTS THAT BIND IGE | May 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 19211660 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECT | May 2025 | August 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 19208792 | ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER | May 2025 | October 2025 | Allow | 5 | 1 | 1 | No | No |
| 19205170 | NOVEL CYTOKINE-BASED THERAPIES AND METHODS | May 2025 | February 2026 | Allow | 10 | 1 | 1 | No | No |
| 19198946 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | May 2025 | January 2026 | Allow | 8 | 2 | 0 | No | No |
| 19198507 | ANTIBODIES THAT BIND TNFRSF25 | May 2025 | July 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19194986 | IMMUNOTHERAPEUTIC COMPOSITION FOR PREVENTION OF OBESITY, NONALCOHOLIC FATTY LIVER DISEASE AND HYPERTRIGLYCERIDEMIA, AND METHODS OF USE AND PREPARATION THEREOF | April 2025 | October 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 19193079 | BISPECIFIC AGONISTIC ANTIBODIES TO ACTIVIN A RECEPTOR LIKE TYPE 1 (ALK1) | April 2025 | August 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 19193595 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING | April 2025 | March 2026 | Allow | 10 | 2 | 0 | No | No |
| 19193629 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING | April 2025 | October 2025 | Allow | 5 | 2 | 0 | No | No |
| 19193652 | CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19190098 | COMBINATION OF LURBINECTEDIN AND IMMUNE CHECKPOINT INHIBITORS | April 2025 | December 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 19188549 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | April 2025 | July 2025 | Allow | 3 | 1 | 0 | No | No |
| 19189163 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING AN OLIGONUCLEOTIDE TO A SUBJECT | April 2025 | September 2025 | Allow | 5 | 1 | 0 | No | No |
| 19187342 | IL31-BINDING POLYPEPTIDES AND USES THEREOF | April 2025 | August 2025 | Allow | 4 | 0 | 0 | No | No |
| 19182382 | METHODS OF TREATING GASTROINTESTINAL INFLAMMATORY DISEASE | April 2025 | July 2025 | Allow | 3 | 1 | 0 | No | No |
| 19180749 | ALBUMIN BINDING PROTEINS AND METHODS OF USE | April 2025 | September 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19180751 | Methods and compositions for improving the immune response against viral pathogens | April 2025 | December 2025 | Abandon | 8 | 1 | 0 | No | No |
| 19175619 | PTK7-Binding Proteins | April 2025 | September 2025 | Allow | 6 | 0 | 1 | No | No |
| 19172374 | ANTIGEN BINDING POLYPEPTIDES | April 2025 | July 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19171920 | LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONS | April 2025 | January 2026 | Abandon | 9 | 1 | 0 | No | No |
| 19094954 | RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use | March 2025 | October 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 19092641 | PROCESS OF PURIFICATION OF PROTEIN | March 2025 | December 2025 | Allow | 9 | 1 | 0 | No | No |
| 19093136 | BISPECIFIC ANTI-HUMAN A-BETA/ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES | March 2025 | June 2025 | Allow | 2 | 1 | 1 | No | No |
| 19085020 | TSLP-Binding Molecules, IL-33-Binding Molecules, and Bispecific Antigen-Binding Molecules, and Uses Thereof | March 2025 | October 2025 | Allow | 7 | 1 | 0 | No | No |
| 19085184 | ANTI-HUMAN INTERLEUKIN 36 RECEPTOR MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF TO TREAT DISEASE | March 2025 | October 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 19081458 | PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | March 2025 | October 2025 | Allow | 7 | 1 | 0 | No | No |
| 19081340 | PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF | March 2025 | January 2026 | Allow | 10 | 1 | 1 | No | No |
| 19073405 | FUS PROTEOLYSIS-TARGETING CHIMERA, PREPARATION METHOD AND APPLICATIONS THEREOF | March 2025 | May 2025 | Allow | 3 | 0 | 0 | No | No |
| 19074158 | PLATELET DERIVATIVE COMPOSITIONS, AND PLURALITIES OF CONTAINERS CONTAINING SAME | March 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 19073422 | CD142 ANTIBODIES, ANTIBODY-DRUG CONJUGATES, PREPARATIONS AND USES THEREOF | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 19071424 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | March 2025 | August 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19069168 | FC FRAGMENTS THAT BIND FCRN AND METHODS OF USE | March 2025 | January 2026 | Abandon | 10 | 1 | 1 | Yes | No |
| 19066279 | EXOSOME SYSTEMS, PRODUCTS AND METHODS | February 2025 | April 2025 | Allow | 1 | 0 | 0 | No | No |
| 19067809 | Nectin-4 binding miniproteins, conjugates and methods of use thereof | February 2025 | July 2025 | Allow | 4 | 1 | 0 | No | No |
| 19065094 | ANTIBODIES TO CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AND USES THEREOF | February 2025 | December 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 19065946 | MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING OF EXON 44 OF DYSTROPHIN IN A SUBJECT | February 2025 | May 2025 | Allow | 2 | 0 | 1 | Yes | No |
| 19066035 | Complexes Comprising An Anti-transferrin Receptor Antibody Linked to An Oligonucleotide And Method Of Delivering Oligonucleotide To A Subject | February 2025 | June 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19064325 | CD4+ T CELLS EXPRESSING IL-10 AND CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | February 2025 | November 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 19064273 | ANTI-CEACAM5 ANTIBODY DRUG CONJUGATES | February 2025 | September 2025 | Allow | 6 | 1 | 0 | No | No |
| 19064618 | MODIFIED K562 FEEDER CELL LINE EXPRESSING FACTORS THAT ENHANCE THE ACTIVATION AND PROLIFERATION OF NATURAL KILLER CELLS AND A METHOD FOR ITS PRODUCTION | February 2025 | March 2026 | Allow | 13 | 2 | 1 | No | No |
| 19063190 | COMPOSITIONS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND METHODS FOR MAKING AND USING THE SAME | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19063195 | COMPOSITIONS TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS FOR MAKING AND USING THE SAME | February 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 19061157 | METHODS OF TREATING INFLAMMATORY AND/OR ALLERGIC DISORDERS WITH NORKETOTIFEN | February 2025 | December 2025 | Abandon | 9 | 1 | 1 | No | No |
| 19059303 | METHOD FOR IDENTIFYING A SHARED NEOANTIGEN-REACTIVE T CELL RECEPTOR | February 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 19058780 | ANTIBODIES THAT BIND THE SPIKE PROTEIN OF SARS-COV-2 | February 2025 | September 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 19053626 | ANTI-PTK7 ANTIBODY AND USES THEREOF | February 2025 | October 2025 | Allow | 8 | 1 | 0 | No | No |
| 19050002 | ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES | February 2025 | July 2025 | Allow | 6 | 1 | 0 | No | No |
| 19050008 | NK/MONOCYTE ENGAGERS | February 2025 | July 2025 | Allow | 6 | 2 | 1 | No | No |
| 19048808 | Production of Biosimilar Ustekinumab In CHO Cells | February 2025 | March 2026 | Allow | 13 | 2 | 1 | Yes | No |
| 18727602 | BIOMARKER FOR PREDICTING THE PROGNOSIS OF COLORECTAL CANCER | February 2025 | December 2025 | Allow | 17 | 1 | 1 | No | No |
| 19046824 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING | February 2025 | May 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19043567 | HUMANIZED ANTI-TISSUE FACTOR ANTIBODY, ANTIBODY-DRUG CONJUGATE PREPARED THEREFROM AND USE THEREOF | February 2025 | June 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19036915 | ANTIBODIES THAT BIND TNFRSF25 | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19035322 | N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES | January 2025 | January 2026 | Allow | 12 | 1 | 1 | Yes | No |
| 19035354 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOF | January 2025 | September 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 19034098 | METHODS FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19033679 | ANTIBODIES TARGETING IL3 | January 2025 | May 2025 | Allow | 4 | 1 | 1 | No | No |
| 19032782 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19032739 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19031443 | ENGINEERED DENDRITIC CELL AND USE THEREOF | January 2025 | December 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 19030138 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA | January 2025 | July 2025 | Allow | 6 | 1 | 0 | No | No |
| 19030161 | ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA | January 2025 | July 2025 | Allow | 6 | 1 | 0 | No | No |
| 19026296 | MRNA VACCINE ENCODING FUSION ANTIGEN AGAINST MPOX AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1640.
With a 29.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1640 is part of Technology Center 1600. This group has examined 106,748 patent applications in our dataset, with an overall allowance rate of 54.1%. Applications typically reach final disposition in approximately 34 months.
Applications in Group 1640 receive an average of 1.92 office actions before reaching final disposition. The median prosecution time is 34 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.